High expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis - 23/02/21
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
Abstract |
Introduction |
Sarcoidosis is a systemic granulomatous disease with a variable clinical presentation and disease course. There is still no reliable biomarker available, which assists in the diagnosis or prediction of the clinical course. According to a murine model, the expression level of the metabolic checkpoint kinase mechanistic target of Rapamycin complex 1 (mTORC1) in granulomas of sarcoidosis patients may be used as a clinical biomarker.
Material and methods |
This is a retrospective analysis of 58 patients with histologically confirmed sarcoidosis. Immunohistochemical staining of granulomas from tissue samples was evaluated for the expression of activated mTORC1 signaling, including phosphorylated mTOR, its downstream effectors S6K1, 4EBP1 and the proliferation marker Ki-67. Patients were categorized according to different clinical phenotypes, serum biomarkers, and immunomodulatory therapy.
Results |
All patients showed activated mTORC1 signaling in granulomas, which correlated with its downstream effectors S6K1 and 4EBP1 but was not related to Ki-67 expression. The mTORC1 activity revealed an association neither to disease severity nor the necessity of treatment; however, p-mTOR inversely correlated with cumulative corticosteroid dosage.
Conclusion |
Our data confirm activation of the mTORC1 pathway in sarcoidosis, supporting the hypothesis that mTOR is a significant driver in granuloma formation. However, we could not find a relationship between the degree of mTOR activation and disease severity or the need for therapy.
Le texte complet de cet article est disponible en PDF.Highlights |
• | mTORC1 activation associated with granuloma formation in mice. |
• | Potential clinical biomarker and therapeutic target for sarcoidosis. |
• | High expression of mTOR and downstream effectors in sarcoid granulomas. |
• | mTOR activation neither related to disease severity nor the need for therapy. |
Keywords : Sarcoidosis, mTOR, Biomarker, Prognosis, Clinical study
Plan
Vol 177
Article 106294- février 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?